Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR ...

There has been a sharp increase in colorectal and pancreatic cancer rates among Americans under 55 years, despite declines in older adults, according to a new study.

Among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), racial and ethnic minority patients and socially ...

U.S. medical centers are seeking FDA authorization for the compassionate use — or expanded access — of Namodenoson for ...

With Trump's tariffs looming, is this really the appropriate time to load up on pharma stocks? And where does Cipla stand in ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

Investigators from Canada and the UK conducted a systematic review and meta-analysis to update evidence associating eradication of Helicobacter pylori with reduced gastric cancer risk.

MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced three poster presentations at the 2025 American ...